BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

Stopped The study protocol was withdrawn because, after modifications, the study transitioned from an Investigator-Initiated Trial (IIT) to an Investigational New Drug (IND) clinical trial. This change necessitated a multi-center approach.

Conditions

• AL Amyloidosis

Interventions

• DRUG: CM-336 BCMA/CD3 bispecific antibody

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

• [object Object]